cell in Medical Technology

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced results from a study released by Dartmouth-Hitchcock Medical Center at the International Association for the Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer. Th...

World's First Cardiac Adult Stem Cell Patient Receives Infusion

Trial taking place in Louisville, KY LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- Michael (Mike) Jones has become the world's first recipient of adult cardiac stem cells to treat congestive heart failure. Jones' infusion on July 17 marks the world's first phase-one...

Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity

EMERYVILLE, Calif., July 17 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates will be published in Public Library of Science One. ...

Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy

SUNRISE, Fla., July 7 /PRNewswire-FirstCall/ -- Bioheart, Inc., (OTC Bulletin Board: BHRT) announced today that the panel discussion on myoblast (muscle stem cell) therapy between distinguished physicians and scientists is available for playback at the following site: http://www.bioheartin...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines wit...

Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries

Stem Cell Technologies for Surgery TEXARKANA, Texas, June 5 /PRNewswire/ -- A new breakthrough in adult stem cell technology has three Texarkana neurosurgeons leading their industry by utilizing concentrated stem cells for spine surgery. The innovative technique is improving the desired resul...

Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) the market leader in laser transmyocardial revascularization (TMR) for the treatment of chronic cardiac ischemia, announces that Dr. Naresh Trehan of New Delhi will be presenting his clinical results of ...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, d...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

Small Molecule Stem Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic Malignancy LA JOLLA, Calif., May 27 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem C...

New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns

NIH Should Fix Standards to Allow Use of Current Stem Cell Lines SANTA MONICA, Calif., May 20 /PRNewswire-USNewswire/ -- -- Regulations governing stem cell research proposed by the Obama Administration -- unless modified before final implementation on July 1 -- prohibit federal fund...

Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings

BERGISCH GLADBACH, Germany, May 20 /PRNewswire/ -- Miltenyi Biotec announces the worldwide and exclusive release of Myelin Removal Beads. Myelin is a specialized membrane which ensheathes and insulates axons in the peripheral and central nervous system. During preparation of single-cell suspen...

New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease

Study Presented at the American Thoracic Society by Researchers at The Children's Hospital of Philadelphia Confirms Accuracy and Clinical Value of Noninvasive SpCO(R) and SpMet(R) IRVINE, Calif., May 19 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(T...

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

HOUSTON, May 19 /PRNewswire/ -- Agennix announced today that talactoferrin alfa (talactoferrin) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent(R) - Pfizer). ...

BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available

ARLINGTON, Va., May 5 /PRNewswire/ -- BioInformatics, LLC announces the release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. Despite a sluggish economy and cuts being made to laboratory budgets, the market for stem cell research products is expected to increa...

An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients

The results of the largest study performed to date will be presented during the International Society for Heart and Lung Transplantation Annual Meeting in Paris, France on April 24, 2009 COLUMBIA, Md., April 24 /PRNewswire/ -- Since it was cleared as an in vitro assessment of cell-mediate...

SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production

ST. LOUIS, April 23 /PRNewswire-FirstCall/ -- SAFC Biosciences(R), a business segment within SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: SIAL ), today announced the introduction of EX-CELL(TM) EBx (R) cell growth and viral production media designed exclusively to support Vivalis' (NY...

Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin

Identifies potential clinical trial strategies for personalized approach to cancer treatment SEATTLE, April 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC), presented data from a preclinical study, whic...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today reported on an NIH-funded, pre-clinical study conducted by independent researchers at the University of Cincinnati entitled IGF-1--Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell ...

Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that it has reached its enrollment target of 400 patients in the SPEAR (Study of Picoplatin Efficacy After Relapse) tria...

Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

HAYWARD, Calif., March 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data from the first cohort of 30 patients, an independent Data S...

MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer

WOONSOCKET, R.I., March 19 /PRNewswire-FirstCall/ --MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of liver stem cells and liver cancer. ...

Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers

FORT WORTH, Texas, March 16 /PRNewswire/ -- Healthpoint today announced that it has initiated a Phase II clinical trial investigating the efficacy of HP802-247 in venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The study is designed to determine the...

Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

CALGARY, March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients w...

Roundtable Calls President's Embryonic Stem Cell Decision: Bankrupt

CLEVELAND, March 9 /PRNewswire-USNewswire/ -- In response to the President's actions today changing federal policy on embryonic stem cell research, David Zanotti, CEO of the American Policy Roundtable and Dr. Charles McGowen, M.D., Chief Medical Advisor for the Roundtable, issued the following sta...

Drug Development Program Started Based on CAP(R) Human Cell Line

COLOGNE, Germany, March 3 /PRNewswire/ -- - New Platform May Provide Solutions for Many RA-Patients Around the World Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce the sta...

Michigan Catholic Conference Welcomes Announcement of Non-Embryo Destructive Stem Cell Research Advancement

LANSING, Mich., March 2 /PRNewswire-USNewswire/ -- Michigan Catholic Conference Vice President for Public Policy Paul Long made the following statement today regarding a study in the online journal Nature, and reported in today's Washington Post, that stem cell researchers have discovered an addit...

A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe

Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare is...

Wayne County Partners With TechTown to Launch Global Stem Cell 'Innovation and Commercialization Lab'

2,500-square-foot 'open lab' will serve as international hub for collaborative research, biotech start-ups DETROIT, Feb. 16 /PRNewswire-USNewswire/ -- TechTown, the Wayne State University research and technology park, will soon be home to the first stem cell commercialization lab in Michiga...

Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

SEATTLE, Jan. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that after communication with the Food and Drug Administration (FDA), CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to ...

FDA Stem Cell Approval Breakthrough Laudable

SAN CLEMENTE, Calif., Jan. 23 /PRNewswire/ -- Today the FDA announced approval for the first clinical trials on humans using Embryonic Stem Cells but Adult Stem Cell scientist Christian Drapeau says the experts may not be telling the whole story; Adult Stem Cells have greater potential with le...

UK Must Maintain its Momentum in Stem Cell Expertise

LONDON, January 19 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today the UK must 'maintain its momentum' to deliver pioneering stem cell treatments if it is to remain at the forefront of medical technology. Professor Sir Christoph...

Stem Cell Pioneer to Speak to A.L.L. Personhood Conference

WASHINGTON, Jan. 12 /PRNewswire-USNewswire/ -- American Life League's historic Personhood Conference is featuring one the foremost pioneers in adult stem cell research and regenerative medicine. (Logo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) Dr. Theresa Deisher, fou...

Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of a proof-of-concept clinical trial of SLC022 in patients with post-herpetic neuralgia (PHN). PHN, a painful co...

Gene Marker May Improve Odds of Stem Cell Therapies for Disease

PHILADELPHIA, Jan. 9 /PRNewswire-USNewswire/ -- A single tumor-suppressor gene may provide a unique marker for senescence in Mesenchymal stem cells (MSCs) in vitro, while also playing a role in moving MSCs into senescence, researchers at the Human Health Foundation and the Sbarro Institute for Can...

Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients

BEIJING, Jan. 7 /PRNewswire/ -- Tiantan Puhua Hospital Stem Cells Center ( http://www.stemcellspuhua.com ), the worldwide leader in using stem cells to effectively treat neurological disorders, announced today six new globally experienced additions to its medical and research staff that significan...

Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes

SAN FRANCISCO, Dec. 7 /PRNewswire-USNewswire/ -- Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes will be explored at a press conference taking place on Sunday, December 7, at 8:00 a.m., during the 50th Annual Meeting of the American Socie...

Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- A study assessing the quality of care for patients with sickle cell disease in a variety of hospital settings will be presented at a press conference on Saturday, December 6, at 9:30 a.m., during the 50th Annual Meeting of the American Society of He...

Gene Therapy Corrects Sickle Cell Disease in Laboratory Study

New St. Jude treatment alleviates long-term anemia and organ damage in mice and paves the way for human applications MEMPHIS, Tenn., Dec. 3 /PRNewswire-USNewswire/ -- Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children's Research Hos...

Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity

St. Jude study shows the Prox1 gene is a two-way switch that, if turned off, causes lymphatic endothelial cells to be reprogrammed so that they lose their identity and become more like blood endothelial cells MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswire/ -- Scientists at St. Jude Childr...